Admission neutrophil-to-lymphocyte ratio (NLR) has proven to predict adverse events in patients with ST-elevation Myocardial Infarction (STEMI).– New evidence has shown that NLR continues to increase within 48-72 hours in patients who develop worse outcomes. Therefore, this study sought to compare the prognostic capacity of admission and late NLR for adverse events in patients with STEMI undergoing primary percutaneous coronary intervention (pPCI).
[…]
Early vs. Late Neutrophil-To-Lymphocyte Ratio for the Prediction of Adverse Outcomes in Patients with STEMI Undergoing Primary PCI
MachadoGP, AraujoGN, MaltauroD, CustodioJ, MilanV, WainsteinM. Early vs. Late Neutrophil-To-Lymphocyte Ratio for the Prediction of Adverse Outcomes in Patients with STEMI Undergoing Primary PCI. Arq. Bras. Cardiol. 2021;116(3):504-6.
Machado,Guilherme Pinheiro; Araujo,Gustavo Neves de; Maltauro,Daniele; Custodio,Julia; Milan,Victoria; Wainstein,Marco. Early vs. Late Neutrophil-To-Lymphocyte Ratio for the Prediction of Adverse Outcomes in Patients with STEMI Undergoing Primary PCI. Arq. Bras. Cardiol., v. 116, n. 3, p. 504-506, Mar. 2021.
Machado,G.P., Araujo,G.N. , Maltauro,D., Custodio,J., Milan,V., & Wainstein,M. (2021). Early vs. Late Neutrophil-To-Lymphocyte Ratio for the Prediction of Adverse Outcomes in Patients with STEMI Undergoing Primary PCI. Arq. Bras. Cardiol.,116(3), 504-506.
Machado,Guilherme Pinheiro and Araujo,Gustavo Neves de and Maltauro,Daniele and Custodio,Julia and Milan,Victoria and Wainstein,Marco. Early vs. Late Neutrophil-To-Lymphocyte Ratio for the Prediction of Adverse Outcomes in Patients with STEMI Undergoing Primary PCI. Arq. Bras. Cardiol. [online]. 2021, vol. 116, n. 3, [cited 2025-09-08], pp.504-506. Available from: <https://abccardiol.org/en/article/early-vs-late-neutrophil-to-lymphocyte-ratio-for-the-prediction-of-adverse-outcomes-in-patients-with-stemi-undergoing-primary-pci/>. ISSN 0066-782X.
Figure 1
Receiver operator characteristic (ROC) graph showing areas under the curve (AUC) of admission neutrophil–to–lymphocyte ratio (NLR) and late NLR for (A) in-hospital death, (B) in-hospital major cardiovascular outcomes (MACE), (C) one-year all-cause mortality, and (D) one-year MACE